Schond L. Greenway
CIK 1848205 · Chief Financial Officer · last filed 2024-03-26
Schond L. Greenway is a Chief Financial Officer who has filed 13 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing shows the insider had shares withheld for taxes covering $54.4K of MNMD on Mar 26, 2024. Across all open-market trades the lifetime net is −$149.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $57.3K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$57.3K
3
13
-$149.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Financial Officer | 211,057 | $15.00 | $3.17M | -$154.3K | 10 | 2024-03-26 |
| AVTX | CFO | 3,883 | $14.76 | $57.3K | $3.5K | 1 | 2021-12-14 |
| Avalo Therapeutics, Inc. (CERC) Delisted | CFO | 1,652 | $2.93 | $4.8K | $1.7K | 2 | 2021-06-14 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Tax (F) | −5,560 | -$54.4K | EDGAR |
| 2024-02-29 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −5,652 | -$20.5K | EDGAR |
| 2023-09-25 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −5,762 | -$20.6K | EDGAR |
| 2023-08-28 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −20,000 | -$76.0K | EDGAR |
| 2023-06-27 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −11,635 | -$37.2K | EDGAR |
| 2023-04-24 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | +175,000 | $0 | EDGAR |
| 2023-03-17 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | +175,000 | $0 | EDGAR |
| 2022-06-03 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | +1,270,000 | $0 | EDGAR |
| 2022-05-23 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | +1,270,000 | $0 | EDGAR |